Almotriptan Malate Patent Expiration

Almotriptan Malate is Used for relieving symptoms of migraines. It was first introduced by Janssen Pharmaceuticals Inc in its drug Axert on May 7, 2001. 4 different companies have introduced drugs containing Almotriptan Malate.


Almotriptan Malate Patents

Given below is the list of patents protecting Almotriptan Malate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Axert US5565447 Indole derivatives May 07, 2015

(Expired)

Janssen Pharms
Axert US5565447

(Pediatric)

Indole derivatives Nov 07, 2015

(Expired)

Janssen Pharms



Almotriptan Malate Generics

Several generic applications have been filed for Almotriptan Malate. The first generic version for Almotriptan Malate was by Teva Pharmaceuticals Usa and was approved on Jul 7, 2015. And the latest generic version is by Ajanta Pharma Ltd and was approved on Mar 3, 2016.

Given below is the list of companies who have filed for Almotriptan Malate generic.


1. AJANTA PHARMA LTD

Ajanta Pharma Ltd has filed for 2 different strengths of generic version for Almotriptan Malate. Given below are the details of the strengths of this generic introduced by Ajanta Pharma Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 6.25MG BASE tablet Prescription ORAL AB Mar 3, 2016
EQ 12.5MG BASE

(reference standard)

tablet Prescription ORAL AB Mar 3, 2016


2. MYLAN

Mylan Pharmaceuticals Inc has filed for 2 different strengths of generic version for Almotriptan Malate. Given below are the details of the strengths of this generic introduced by Mylan.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 6.25MG BASE tablet Prescription ORAL AB Nov 9, 2015
EQ 12.5MG BASE tablet Prescription ORAL AB Nov 9, 2015


3. TEVA PHARMS USA

Teva Pharmaceuticals Usa has filed for 2 different strengths of generic version for Almotriptan Malate. Given below are the details of the strengths of this generic introduced by Teva Pharms Usa.

Strength Dosage Form Availability Application Pathway TE code Launch Date
EQ 6.25MG BASE tablet Prescription ORAL AB Jul 7, 2015
EQ 12.5MG BASE tablet Prescription ORAL AB Jul 7, 2015